The real story is that per capita spending on the program, accounting for inflation and population growth, remains where it ...
Melbourne biotech Magellan Stem Cells is 17 years old and about to begin a pivotal Phase 3 trial of its stem cell treatment ...
A small Melbourne company founded by two medical researchers has landed one of Australia's biggest potential licensing deals.
Net spending on the Pharmaceutical Benefits Scheme rose by about $1.5 billion in 2025-26 as rebates paid by medicine ...
Dr Brian McNamee AO will retire from CSL's board in March next year, and Gordon Naylor, who has served as Interim CEO and Managing Director since February, will become the company's chair.
The current agreement between the Commonwealth and the research-based pharmaceutical industry promised faster access to new medicines through HTA reforms. Four years on, that reform is still ...
The melanoma study's principal investigator, Professor Georgina Long of Melanoma Institute Australia, said the results ...
Telix Pharmaceuticals has reaffirmed that it will pass US$1 billion in revenue and other income this year. Its third-quarter ...
The Department of Health, Disability and Ageing has committed significant resources to a Canberra consultancy to build a new "charging model" for assessing medicines, vaccines and medical devices for ...
Algorae Pharmaceuticals has signed two agreements with Mumbai-based manufacturer Umedica Laboratories. Together, they give ...
In a discussion with BioPharmaDispatch, Professor Hill said the starting point was a set of management questions she put to ...
A year ago, Professor Richard Scolyer, who was living with glioblastoma, stood in Parliament House in Canberra and urged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results